Metsera (NASDAQ:MTSR) Given Overweight Rating at Cantor Fitzgerald

Key Points

• Metsera's stock has received an "overweight" rating from Cantor Fitzgerald, reaffirming analysts' confidence in the company.
• Guggenheim and Bank of America have both raised their target price on Metsera's shares, indicating a positive outlook with reviews of "buy" ratings.
• Metsera is a clinical-stage biopharmaceutical company focusing on developing innovative treatments for obesity and related conditions, with promising products in its pipeline.

Cantor Fitzgerald restated their overweight rating on shares of Metsera (NASDAQ:MTSR - Free Report) in a research note published on Wednesday morning,Benzinga reports.

Other research analysts have also recently issued reports about the company. Wells Fargo & Company began coverage on Metsera in a research report on Friday, June 20th. They set an "overweight" rating and a $65.00 price objective on the stock. Guggenheim lifted their price target on shares of Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a report on Tuesday, June 10th. Bank of America upped their price target on shares of Metsera from $45.00 to $50.00 and gave the stock a "buy" rating in a research report on Thursday, August 28th. Finally, Wall Street Zen raised shares of Metsera from a "sell" rating to a "hold" rating in a research note on Saturday, August 30th. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $59.00.

Metsera Stock Down 1.2%

MTSR stock traded down $0.42 during midday trading on Wednesday, reaching $35.87. 1,520,674 shares of the company's stock traded hands, compared to its average volume of 1,208,677. Metsera has a 52-week low of $12.30 and a 52-week high of $47.40. The stock's 50-day moving average is $34.73 and its 200 day moving average is $28.67.

Metsera (NASDAQ:MTSR - Get Free Report) last issued its quarterly earnings results on Monday, July 28th. The company reported ($0.66) earnings per share for the quarter.

Institutional Trading of Metsera

A number of institutional investors and hedge funds have recently bought and sold shares of MTSR. Osaic Holdings Inc. lifted its stake in Metsera by 45.5% in the 2nd quarter. Osaic Holdings Inc. now owns 946 shares of the company's stock worth $27,000 after purchasing an additional 296 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of Metsera by 100.0% during the second quarter. BNP Paribas Financial Markets now owns 1,600 shares of the company's stock valued at $46,000 after purchasing an additional 800 shares in the last quarter. Virtus Investment Advisers LLC bought a new stake in shares of Metsera in the second quarter worth about $77,000. Strs Ohio purchased a new stake in shares of Metsera in the first quarter worth about $76,000. Finally, Police & Firemen s Retirement System of New Jersey lifted its position in shares of Metsera by 32.6% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 4,293 shares of the company's stock worth $122,000 after buying an additional 1,056 shares in the last quarter.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.